Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy

BJU International

Volumn 99, Issue 2, 2007, Pages 311-314

  Hsu, Chao Yu ^a   Joniau, Steven ^a   Roskams, Tania ^a   Oyen, Raymond ^a   Van Poppel, Hein ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Androgen deprivation therapy; cT3; Neoadjuvant; Prostate cancer

Indexed keywords

ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846230635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06559.x     Document Type: Article

References (17)

1. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51
2. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2006; doi:10.1016/j.eururo.2006.05.024
3. Van Poppel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995; 154: 429-34
4. Hsu CY, Joniau S, Van Poppel H. Radical prostatectomy for locally advanced prostate cancer: technical aspects of radical prostatectomy. EAU Update Series 2005; 3: 90-7
5. Sobin LH, Wittekind C. TNM Classification of Prostate Cancer. 6th edn. New York: Wiley-Liss, 2002: 184-7
6. Maeda O, Meguro N, Saiki S et al. [Neoadjuvant endocrine therapy in patients with locally advanced prostate cancer]. Hinyokika Kiyo 1996; 42: 821-7
7. Ogura Y, Sakata Y, Wakita T, Hayashi N, Hioki T, Sugimura Y. [Treatment results of radical prostatectomy in clinical stage B and C prostate cancer: comparison of the neoadjuvant therapy group versus the surgery group; retrospective analysis of 80 cases]. Hinyokika Kiyo 2003; 49: 515-20
8. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706-13
9. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3, N0, M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (Suppl. 3A): 65-9
10. Swindle P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005; 174: 903-7
11. Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 2016-9
12. Nelson BA, Shappell SB, Chang SS et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2006; 97: 1169-72
13. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999; 162: 2024-8
14. Lorente JA, Arango O, Bielsa O, Cortadellas R, Lloreta-Trull J, Gelabert-Mas A. A longer duration of neoadjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumor volume of localized prostate cancer. Eur Urol 2003; 43: 119-23
15. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 709-13
16. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233-40
17. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138-42